AtaiBeckley Inc. - Common Stock (NQ:ATAI)

7.350 UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AtaiBeckley Inc. - Common Stock

< Previous 1 2

...

25 26 27 28 29 30 31 32 Next >

North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026

December 14, 2021

Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept...

Via FinancialNewsMedia

Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments ↗

December 13, 2021

Image provided by Flickr The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...

Via Benzinga

Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness ↗

December 13, 2021

Photo by Raimond Klavins

Via Benzinga

Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline ↗

December 12, 2021

The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same...

Via Talk Markets

Topics Cannabis

Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study ↗

December 09, 2021

Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The...

Via Benzinga

Topics Derivatives

National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000 ↗

December 08, 2021

The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics...

Via Benzinga

Topics Death

This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness ↗

December 08, 2021

Photo by Michael Longmire on...

Via Benzinga

Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways

December 07, 2021

Via Investor Brand Network

New York's Horizons Psychedelic Conference Highlights Big Donations In The Growing Industry ↗

December 07, 2021

Venture capitalist and businessman Stephen Jurvetson is joining an expanding group of prominent invest...

Via Benzinga

Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November ↗

December 01, 2021

A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance.

Via Talk Markets

Topics Cannabis

Analyst Ratings For ATAI Life Sciences ↗

November 30, 2021

Over the past 3 months, 6 analysts have published their opinion on ATAI Life Sciences (NASDAQ:

Via Benzinga

Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways ↗

November 29, 2021

Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a ...

Via Benzinga

Psychedelic Drug Stocks Continued To Decline Last Week ↗

November 21, 2021

The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021 ↗

November 30, 2021

Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ:

Via Benzinga

Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November ↗

November 14, 2021

Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September.

Via Talk Markets

Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others ↗

November 11, 2021

Compass Pathways reported

Via Talk Markets

Use of Ketamine for Mental Disorders Rising While New Therapies Emerge

November 17, 2021

Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion...

Via FinancialNewsMedia

Analyst Ratings For ATAI Life Sciences ↗

November 11, 2021

Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ:AT...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2021 ↗

November 11, 2021

Upgrades Barrington Research upgraded the previous rating for Clear Channel Outdoor Holdings Inc (NYSE:

Via Benzinga

70 Biggest Movers From Yesterday ↗

November 16, 2021

Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The...

Via Benzinga

Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial ↗

November 09, 2021

Shares plunged, despite a psilocybin-based drug reducing depression in a trial.

Via Investor's Business Daily

NetworkNewsAudio – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers Hope on the Smoking-Cessation Horizon

November 04, 2021

Via Investor Brand Network

This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop ↗

November 02, 2021

Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O’Leary and Peter Thiel recognizing the potential in the psych drug...

Via Benzinga

ATAI Life's Schizophrenia Candidate Shows Promising Action In Mid-Stage Study ↗

November 01, 2021

ATAI Life Sciences NV (NASDAQ: ATAI) announced interim data from the first 8-patient cohort of its Phase 2a trial of RL-007 for Cognitive Impairment Associated...

Via Benzinga

Increasing Prevalence of Depression & Mental Health Disorders Fueling Huge Growth in Psychedelic Drugs Market

November 04, 2021

Palm Beach, FL –November 4, 2021 – FinancialNewsMedia.com News Commentary – The pace of society’s change in attitude to the use of psychedelics has been amazing. It has gone from a “Born To Be Wild”,...

Via FinancialNewsMedia

Topics Law Enforcement

Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148% ↗

October 24, 2021

The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD.

Via Talk Markets

Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021 ↗

October 15, 2021

Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month.

Via Talk Markets

Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More

November 01, 2021

Via Investor Brand Network

Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention

October 27, 2021

Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been...

Via FinancialNewsMedia

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

The Week In Psychedelics

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.